Evotec Regains Rights to Eliapixant From Bayer
February 04 2022 - 7:37AM
Dow Jones News
By Chris Wack
Evotec SE on Friday said Bayer AG is discontinuing the
development of the investigational P2X3 receptor antagonist
eliapixant, which stems from a former joint company multitarget
research alliance.
Evotec said that following a review of the available data, Bayer
concluded the overall benefit no longer outweighs the risk in the
actively pursued indications.
Evotec said it regains the rights to all P2X3 assets. The
company said it will evaluate the underlying data once available
and consider all options.
Evotec shares fell 10% to $18.50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 04, 2022 08:22 ET (13:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2024 to May 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From May 2023 to May 2024